| Literature DB >> 27550090 |
Ren-Peng Zhou1,2, Xiao-Shan Wu1,2, Ya-Ya Xie1,2, Bei-Bei Dai1,2, Wei Hu1,2, Jin-Fang Ge1,2, Fei-Hu Chen3,4.
Abstract
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic, synovial inflammation affecting multiple joints, finally leading to extra-articular lesions for which limited effective treatment options are currently available. Interleukin-34 (IL-34), recently discovered as the second colony-stimulating factor-1 receptor (CSF-1R) ligand, is a newly discovered cytokine. Accumulating evidence has disclosed crucial roles of IL-34 in the proliferation and differentiation of mononuclear phagocyte lineage cells, osteoclastogenesis and inflammation. Recently, IL-34 was detected at high levels in patients with active RA and in experimental models of inflammatory arthritis. Blockade of functional IL-34 with a specific monoclonal antibody can reduce the severity of inflammatory arthritis, suggesting that targeting IL-34 or its receptors may constitute a novel therapeutic strategy for autoimmune diseases such as RA. Here, we have comprehensively discussed the structure and biological functions of IL-34, and reviewed recent advances in our understanding of the emerging role of IL-34 in the development of RA as well as its potential utility as a therapeutic target.Entities:
Keywords: autoimmune; cytokine; inflammation; interleukin-34; rheumatoid arthritis
Mesh:
Substances:
Year: 2016 PMID: 27550090 PMCID: PMC5095491 DOI: 10.1111/imm.12660
Source DB: PubMed Journal: Immunology ISSN: 0019-2805 Impact factor: 7.397